Progress in Medicinal Chemistry (Progress in Medicinal Chemistry) 〈58〉

個数:
電子版価格 ¥21,490
  • 電書あり

Progress in Medicinal Chemistry (Progress in Medicinal Chemistry) 〈58〉

  • 提携先の海外書籍取次会社に在庫がございます。通常2週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。

  • 提携先の海外書籍取次会社に在庫がございます。通常約2週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • 製本 Hardcover:ハードカバー版/ページ数 260 p.
  • 言語 ENG,ENG
  • 商品コード 9780444642776
  • DDC分類 615

Full Description


Progress in Medicinal Chemistry, Volume 58, provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of authors. Topics covered in this new release include Amyotrophic lateral sclerosis (ALS), Covalent-binding Drugs, Natural Product Drug Delivery - A Special Challenge?, and SMN2 gene splicing modifier, and more.

Table of Contents

Contributors                                       vii
Preface ix
1 Covalent binders in drug discovery 1 (62)
Anil Vasudevan
Maria A. Argiriadi
Aleksandra Baranczak
Michael M. Friedman
Julia Gavrilyuk
Adrian D. Hobson
Jonathan J. Hulce
Sami Osman
Noel S. Wilson
1 Introduction 2 (1)
2 Types of covalent binders 3 (23)
3 Structure-based considerations 26 (7)
4 Approved/clinical covalent inhibitors 33 (7)
5 Covalent probes in chemical biology 40 (6)
6 Natural products as ADC payloads 46 (6)
7 Summary 52 (1)
References 53 (9)
Further reading 62 (1)
2 Amyotrophic lateral sclerosis 63 (56)
Klara Valko
Lukasz Ciesla
1 Amyotrophic lateral sclerosis (ALS) 64 (6)
2 Potential cellular signalling pathways 70 (11)
that could be targeted for the treatment
of motoneuron diseases
3 Current markers and animal models used 81 (3)
to evaluate the effect of new
therapeutics in ALS
4 Current medicinal chemistry approaches 84 (21)
5 Summary of current approaches and 105(3)
future directions
Acknowledgements 108(1)
References 108(11)
3 Rewriting the (tran)script: Application 119(38)
to spinal muscular atrophy
Hasane Ratni
Lutz Mueller
Martin Ebeling
1 Introduction 119(1)
2 Splicing modulation 120(3)
3 Spinal muscular atrophy (SMA) 123(2)
4 Discovery of nusinersen 125(2)
5 Discovery of branaplam 127(3)
6 Discovery of risdiplam 130(14)
7 Selectivity of risdiplam compared to 144(6)
other small molecule splicing modifiers
8 Impact of selectivity 150(1)
9 Conclusion 151(1)
References 152(5)
4 Natural product drug delivery: A special 157(1)
challenge?
Neil J. Press
Emilie Joly
Peter Ertl
1 Introduction 158(2)
2 Cyclosporine A 160(2)
3 Doxorubicin 162(2)
4 Insulin 164(3)
5 Rapamycin and analogues 167(4)
6 Penicillin 171(4)
7 Morphine 175(2)
8 Paclitaxel (Taxol®) 177(3)
9 Additional strategies 180(1)
10 Conclusions 181(1)
References 182